Visiting Dana-Farber? See our prescreening and mask requirements.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Jeselsohn is a breast medical oncologist and physician scientist. Dr. Jeselsohn leads a breast cancer translational research lab affiliated with the Molecular and Cellular Oncology Division at Dana-Farber. Her laboratory includes wet laboratory researchers and computational biologists. The work in her laboratory is funded by the NIH, funding from pharmaceutical companies, and internal prestigious award (Barr Award, Dunkin Donut Drives Cancer breakthrough award). Dr. Jeselsohn’s work has led to the identification and characterization of estrogen receptor mutations as the most common genetic mechanism of acquired endocrine resistance in metastatic hormone receptor positive breast cancer. This discovery has led to the development of multiple novel endocrine therapies that are currently in clinical development. Dr. Jeselsohn serves as the co-director of the ER positive breast cancer working group at the breast oncology program at DFCI and is the chair of the Lobular Breast Cancer Alliance. Dr Jeselsohn obtained her M.D. degree from the Hebrew University in Jerusalem. She did her residency in Internal Medicine in the University of Texas SA, Health Science Center and Fellowship in Heme/Onc at Tufts Medical Center. After the completion of her clinical training , she trained in the lab Dr. Myles Brown at the Dana- Farber Cancer Institute.
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions